Jennifer Poirier
Acute Care · Dartmouth, MANPI 1922424571
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.2%), education and food and beverage — rather than concentrated in one kind of arrangement. Nevro Corp. accounts for 84.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,174 and has fallen 98.2% since, to $21 in 2025.
Across 15 payments — averaging $96.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$1K
- Averitas Pharma Inc.$66
- Johnson & Johnson$55
- Janssen Scientific Affairs, LLC$39
- Abbott$21
- Bioventus LLC$17
- plus $31 from 2 others
What the payments were for
- Travel & lodging$75352%
- Food & beverage$26919%
- Education$42129%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 5 | $1,212 |
| Averitas Pharma Inc. | 1 | $66 |
| Johnson & Johnson | 3 | $55 |
| Janssen Scientific Affairs, LLC | 2 | $39 |
| Abbott | 1 | $21 |
| Bioventus LLC | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$1,174
How this compares
$1,442 in reported general payments places this provider in the 80th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 44 | $41,563 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 316 | $9,322 |
| Lidocaine | 78 | $4,846 |
| MovantikNaloxegol Oxalate | 11 | $4,371 |
| Buprenorphine | 27 | $3,550 |
| Oxycodone Hcl | 225 | $3,106 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 104 | $1,996 |
| Morphine Sulfate ErMorphine Sulfate | 71 | $1,756 |
| Gabapentin | 154 | $1,462 |
| Pregabalin | 68 | $1,358 |
| Naloxone Hcl | 16 | $1,028 |
| Diclofenac Sodium | 65 | $856 |
| Celecoxib | 28 | $604 |
| Tramadol Hcl | 95 | $533 |
| Ibuprofen | 19 | $161 |
Paid to pharmacies, not to this prescriber.
Other acute care in Dartmouth
- Jennifer SadeckDartmouth$7K
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Audrey RoseWoburn$58K
- Danielle BeaulieuWest Springfield$21K
- Dawn NaylorBoston$13K
- Rebecca RathburnBoston$13K
- Morgan BowdenBoston$11K
- Javier RiveraBoston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.